Similarly, patients with EGFR-mutant NSCLC postoperatively receiving other EGFR-TKIs (erlotinib, osimertinib or icotinib) also observed a significantly improvement in DFS compared to chemotherapy or placebo, with a better tolerability profile (11, 12). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.